Literature DB >> 33098923

Creatinine-Cystatin C Ratio and Mortality in Patients Receiving Intensive Care and Continuous Kidney Replacement Therapy: A Retrospective Cohort Study.

Chan-Young Jung1, Young Su Joo2, Hyung Woo Kim1, Seung Hyeok Han1, Tae-Hyun Yoo1, Shin-Wook Kang1, Jung Tak Park3.   

Abstract

RATIONALE &
OBJECTIVE: Studies have suggested associations between lower ratios of serum creatinine to cystatin C with both lower muscle mass and adverse clinical outcomes in multiple disease conditions. Identifying risk factors for mortality among patients with acute kidney injury (AKI) undergoing continuous kidney replacement therapy (CKRT) may improve assessment of prognosis. We sought to evaluate the association of creatinine-cystatin C ratio with outcomes in patients with AKI undergoing CKRT. STUDY
DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: 1,588 patients treated with intensive care and CKRT for AKI at a tertiary Korean medical center. PREDICTOR: Baseline serum creatinine-cystatin C ratio at the time of CKRT initiation. OUTCOMES: Age- and sex-adjusted 90-day mortality after CKRT initiation. ANALYTICAL APPROACH: Cox proportional hazard models to estimate the association between creatinine-cystatin C ratio and outcome.
RESULTS: Mean age was 64.7 ± 14.5 years and 635 patients (40.0%) were women. The range of creatinine-cystatin C ratios was 0.08 to 10.48. The 30- and 90-day mortality rates were significantly lower for the higher creatinine-cystatin C ratio groups. Multivariable Cox proportional hazards regression analyses revealed that mortality risk became successively lower across quartiles of greater creatinine-cystatin C ratio. When creatinine-cystatin C ratio was evaluated using cubic spline analyses, risks for both 30- and 90-day mortality were lower with higher creatinine-cystatin C ratios. These associations remained significant even after adjustment for confounding variables. LIMITATIONS: Retrospective analysis, serum creatinine and cystatin C may not be in steady state in the setting of AKI.
CONCLUSIONS: Higher serum creatinine-cystatin C ratios were associated with better survival in patients receiving intensive care and CKRT.
Copyright © 2020 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Creatinine; acute kidney injury (AKI); continuous kidney replacement therapy (CKRT); critical illness; cystatin C; intensive care unit (ICU); mortality; muscle mass; risk assessment

Mesh:

Substances:

Year:  2020        PMID: 33098923     DOI: 10.1053/j.ajkd.2020.08.014

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  10 in total

1.  Normalized Creatinine-to-Cystatin C Ratio and Risk of Diabetes in Middle-Aged and Older Adults: The China Health and Retirement Longitudinal Study.

Authors:  Shanhu Qiu; Xue Cai; Bo Xie; Yang Yuan; Zilin Sun; Tongzhi Wu
Journal:  Diabetes Metab J       Date:  2022-03-07       Impact factor: 5.893

2.  Changes in Mortality According to Creatinine/Cystatin C Ratio in Chronic Kidney Disease and Non-chronic Kidney Disease Patients.

Authors:  Jeong Ah Hwang; Younghoon Song; Jaeun Shin; Eunjung Cho; Shin Young Ahn; Gang Jee Ko; Young Joo Kwon; Ji Eun Kim
Journal:  Front Med (Lausanne)       Date:  2022-03-02

3.  A Novel Application of Serum Creatinine and Cystatin C to Predict Sarcopenia in Advanced CKD.

Authors:  Yu-Li Lin; Chih-Hsien Wang; I-Chen Chang; Bang-Gee Hsu
Journal:  Front Nutr       Date:  2022-02-25

4.  Serum creatinine/cystatin C ratio as a screening tool for sarcopenia and prognostic indicator for patients with esophageal cancer.

Authors:  Chao Zheng; Ellen Wang; Jiang-Shan Li; Kai Xie; Chao Luo; Qi-Yue Ge; Li-Wen Hu; Yi Shen
Journal:  BMC Geriatr       Date:  2022-03-15       Impact factor: 3.921

5.  Relationship between serum creatinine to cystatin C ratio and subclinical atherosclerosis in patients with type 2 diabetes.

Authors:  Yoshitaka Hashimoto; Fuyuko Takahashi; Takuro Okamura; Takafumi Osaka; Hiroshi Okada; Takafumi Senmaru; Saori Majima; Emi Ushigome; Naoko Nakanishi; Mai Asano; Masahide Hamaguchi; Masahiro Yamazaki; Michiaki Fukui
Journal:  BMJ Open Diabetes Res Care       Date:  2022-06

6.  Creatinine-cystatin C ratio and mortality in cancer patients: a retrospective cohort study.

Authors:  Chan-Young Jung; Hyung Woo Kim; Seung Hyeok Han; Tae-Hyun Yoo; Shin-Wook Kang; Jung Tak Park
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-04-27       Impact factor: 12.063

7.  Serum creatinine/cystatin C ratio is a systemic marker of sarcopenia in patients with gastrointestinal stromal tumours.

Authors:  Ping'an Ding; Honghai Guo; Chenyu Sun; Shuya Chen; Peigang Yang; Yuan Tian; Scott Lowe; Qun Zhao
Journal:  Front Nutr       Date:  2022-09-02

8.  Serum creatinine to cystatin C ratio and clinical outcomes in adults with non-dialysis chronic kidney disease.

Authors:  Young Youl Hyun; Kyu-Beck Lee; Hyoungnae Kim; Yaeni Kim; Wookyung Chung; Hayne Cho Park; Seung Hyeok Han; Yun Kyu Oh; Sue Kyung Park; Kook-Hwan Oh
Journal:  Front Nutr       Date:  2022-09-26

9.  Serum Creatinine/Cystatin C Ratio as a Predictor of In-hospital Mortality in Patients Hospitalized with Acute Exacerbation of Chronic Obstructive Pulmonary Disease.

Authors:  Zhixiang Chen; Lei Zha; Xiao Ma; Jing Xu; Dandan Huang; Wenlong Wu; Long Chen; Feng Yang; Weiling Liao; Wenhua Wang
Journal:  Lung       Date:  2022-09-15       Impact factor: 3.777

Review 10.  Assessment of kidney function: clinical indications for measured GFR.

Authors:  Natalie Ebert; Sebastjan Bevc; Arend Bökenkamp; Francois Gaillard; Mads Hornum; Kitty J Jager; Christophe Mariat; Bjørn Odvar Eriksen; Runolfur Palsson; Andrew D Rule; Marco van Londen; Christine White; Elke Schaeffner
Journal:  Clin Kidney J       Date:  2021-02-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.